Results Presented at ASCO 2026

Onconic Therapeutics has released results from the phase 1b clinical trial of its next-generation anticancer drug candidate, Nesuparib, for metastatic and advanced pancreatic cancer. The results showed a median overall survival (mOS) of 14.2 months, and notably, one patient who achieved complete response (CR) has survived for more than 40 months.


At ASCO 2026, Kim Joon, CEO of Onconic Therapeutics, is presenting the clinical results of Nesupareep through a poster presentation. Onconic Therapeutics

At ASCO 2026, Kim Joon, CEO of Onconic Therapeutics, is presenting the clinical results of Nesupareep through a poster presentation. Onconic Therapeutics

View original image

On June 1, Onconic Therapeutics announced that it presented the results of the phase 1b clinical trial of Nesuparib (JPI-547) for metastatic and advanced pancreatic cancer at the American Society of Clinical Oncology (ASCO 2026), held in Chicago, USA, from May 29 to June 2 (local time).


The trial was conducted on 27 patients with metastatic and advanced pancreatic cancer. Nesuparib was administered in combination with the current standard treatments—either gemcitabine plus nab-paclitaxel (GemAbraxane) or modified FOLFIRINOX (mFOLFIRINOX). The proportion of patients with metastatic disease in the GemAbraxane group and the modified FOLFIRINOX group was 79% and 92%, respectively.


In the GemAbraxane combination group, the objective response rate (ORR) was 53.8%, and the disease control rate (DCR) was 92.3%. The mOS was recorded as 14.2 months. This exceeds the mOS of 8.5 months reported for GemAbraxane monotherapy in the previous global MPACT trial.


Notably, 12 out of 13 patients (92.3%) in the GemAbraxane combination group surpassed the median overall survival of 8.5 months, which is the benchmark for standard treatment.


Long-term survival cases were also observed. One patient with metastatic pancreatic cancer achieved complete response for target lesions and, as of the end of December 2025, has survived for more than 40 months. Another patient has maintained survival for over 24 months. As of the data analysis point, four patients continue treatment without disease progression, so the median progression-free survival (mPFS) has not yet been reached.


In exploratory subgroup analyses, therapeutic effects were observed regardless of BRCA mutation status. All patients in the GemAbraxane combination group were BRCA wild-type, and only one patient in the modified FOLFIRINOX group had a BRCA mutation.


Among the four patients in the GemAbraxane combination group with confirmed KRAS mutations, the ORR was 75% and the DCR was 100%. The patient who achieved complete response and survived for over 40 months also had a KRAS mutation but no BRCA mutation.


Nesuparib is an anticancer agent with a dual-inhibition mechanism targeting both PARP and tankyrase. The company explained that this approach induces a 'BRCAness' state in cancer cells—mimicking BRCA mutations—and promotes cancer cell death. In terms of safety, grade 3 or higher severe adverse events occurred in two patients (14.3%) in the GemAbraxane combination group, and there were no drug-related deaths reported.


Nesuparib has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for three types of cancer, including pancreatic cancer. The company is currently conducting pharmacokinetic assessments in a multi-ethnic patient population and, based on these results, is proceeding with a phase 2 clinical trial of Nesuparib as a first-line treatment for metastatic and advanced pancreatic cancer.



Kim Jon, CEO of Onconic Therapeutics, stated, "We have confirmed cases of survival over 40 months and complete response in patients with metastatic pancreatic cancer," adding, "Through the ongoing phase 2 clinical trial, we will further demonstrate the clinical value of Nesuparib."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing